Assembly Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Assembly Biosciences has a total shareholder equity of $41.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $136.8M and $95.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$130.25m |
| Equity | US$41.10m |
| Total liabilities | US$95.73m |
| Total assets | US$136.82m |
Recent financial health updates
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely
Aug 17
Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?
Feb 27We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Nov 09We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jun 08We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jan 11Recent updates
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely
Aug 17Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?
Feb 27We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Nov 09Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end
Oct 05Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce
Jul 20We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jun 08We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jan 11We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Sep 03Assembly Biosciences announces resignation of CFO
Jun 02Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook
Mar 24Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares
Feb 05We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
Dec 14
Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators
Nov 16Assembly Biosciences EPS beats by $0.69, beats on revenue
Nov 05Financial Position Analysis
Short Term Liabilities: ASMB's short term assets ($133.8M) exceed its short term liabilities ($39.2M).
Long Term Liabilities: ASMB's short term assets ($133.8M) exceed its long term liabilities ($56.5M).
Debt to Equity History and Analysis
Debt Level: ASMB is debt free.
Reducing Debt: ASMB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ASMB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ASMB is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 3.3% per year.